Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:01AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.38 Insider Own9.96% Shs Outstand90.62M Perf Week-13.85%
Market Cap67.46M Forward P/E- EPS next Y- Insider Trans-0.89% Shs Float81.59M Perf Month4.23%
Income-31.37M PEG- EPS next Q-0.07 Inst Own29.71% Short Float0.24% Perf Quarter-0.75%
Sales56.54M P/S1.19 EPS this Y-132.14% Inst Trans0.69% Short Ratio0.28 Perf Half Y-18.59%
Book/sh0.09 P/B8.37 EPS next Y- ROA-48.15% Short Interest0.20M Perf Year-34.12%
Cash/sh0.54 P/C1.39 EPS next 5Y- ROE-366.84% 52W Range0.59 - 1.48 Perf YTD-6.25%
Dividend Est.- P/FCF- EPS past 5Y33.09% ROI-276.57% 52W High-49.70% Beta1.07
Dividend TTM- Quick Ratio1.55 Sales past 5Y- Gross Margin97.50% 52W Low25.53% ATR (14)0.11
Dividend Ex-Date- Current Ratio1.62 EPS Y/Y TTM30.54% Oper. Margin-56.02% RSI (14)42.95 Volatility15.23% 14.91%
Employees- Debt/Eq0.54 Sales Y/Y TTM-7.75% Profit Margin-55.49% Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.41 EPS Q/Q-153.52% Payout- Rel Volume1.00 Prev Close0.72
Sales Surprise56.25% EPS Surprise40.00% Sales Q/Q-68.79% EarningsNov 02 AMC Avg Volume703.38K Price0.74
SMA20-16.06% SMA50-3.41% SMA200-11.58% Trades Volume96,925 Change3.07%
Date Action Analyst Rating Change Price Target Change
Dec-03-21Resumed H.C. Wainwright Buy $6
Sep-22-21Upgrade WBB Securities Buy → Strong Buy $6.25
Mar-04-21Initiated Aegis Capital Buy $9
Sep-04-19Upgrade Wedbush Neutral → Outperform $2 → $4
Jul-26-18Initiated Citigroup Buy $8
Apr-21-17Initiated Raymond James Strong Buy
Apr-17-17Reiterated H.C. Wainwright Buy $18 → $14
Apr-12-17Initiated Ladenburg Thalmann Buy $11.25
Apr-11-17Resumed Wedbush Outperform $13
Feb-22-17Upgrade WBB Securities Sell → Hold $7.25
Apr-05-24 03:00PM
Mar-06-24 08:00AM
Feb-15-24 03:15AM
Feb-12-24 08:00AM
04:30PM Loading…
Jan-29-24 04:30PM
Dec-26-23 10:51AM
Dec-22-23 07:30AM
Dec-07-23 08:00AM
Dec-06-23 08:00AM
Nov-30-23 08:00AM
Nov-20-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 07:33PM
04:15PM Loading…
Oct-13-23 10:34AM
Oct-11-23 08:30AM
Sep-29-23 04:51PM
Sep-27-23 08:00AM
Sep-14-23 01:17AM
Sep-07-23 08:00AM
Sep-06-23 04:05PM
Aug-28-23 10:17PM
Aug-16-23 08:00AM
Aug-09-23 06:04AM
Aug-06-23 08:24AM
Aug-03-23 05:25PM
04:08PM Loading…
Jul-31-23 04:30PM
Jul-20-23 05:00PM
Jul-14-23 09:38AM
Jun-26-23 08:00AM
Jun-22-23 08:00AM
Jun-20-23 09:55AM
Jun-13-23 08:00AM
May-14-23 09:06AM
May-11-23 04:51PM
May-03-23 04:30PM
Apr-24-23 08:00AM
Apr-17-23 06:45AM
Apr-04-23 12:44PM
Mar-31-23 08:00AM
Mar-25-23 09:13AM
Mar-23-23 12:35PM
Mar-22-23 05:26PM
Mar-07-23 04:15PM
Mar-03-23 09:14AM
Mar-02-23 04:14PM
Mar-01-23 12:54PM
Feb-28-23 08:00AM
Feb-14-23 08:00AM
Feb-04-23 07:42AM
Feb-01-23 08:00AM
Jan-25-23 11:02AM
Jan-04-23 08:00AM
Dec-01-22 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-23-22 08:00AM
Nov-09-22 05:41AM
Nov-08-22 08:00AM
Nov-07-22 11:58AM
Nov-03-22 07:05PM
Oct-24-22 05:30AM
Oct-17-22 08:00AM
Oct-04-22 08:00AM
Sep-21-22 10:27AM
Sep-20-22 04:05PM
Sep-13-22 08:00AM
Sep-06-22 08:00AM
Aug-09-22 07:25PM
Jul-28-22 06:15AM
Jul-27-22 09:34AM
Jun-27-22 08:00AM
Jun-10-22 06:57AM
May-12-22 03:36PM
May-11-22 05:35PM
May-10-22 05:25PM
Apr-25-22 07:00AM
Apr-14-22 08:00AM
Mar-31-22 08:00AM
Mar-07-22 06:55PM
Mar-03-22 07:11AM
Feb-17-22 03:02PM
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tari LeslieCHIEF SCIENTIFIC OFFICERMar 11 '24Sale0.6721,02914,085258,681Mar 12 09:48 PM
Sandison TaylorChief Medical OfficerMar 11 '24Sale0.6720,66213,839347,095Mar 12 09:47 PM
Ward ShaneCOO & CLOMar 11 '24Sale0.6720,47313,713198,770Mar 12 09:46 PM
Shah PreetamCFO & CBOMar 11 '24Sale0.6718,93112,680227,210Mar 12 09:45 PM
Sandison TaylorChief Medical OfficerSep 11 '23Sale0.9518,79317,810363,757Sep 13 04:22 PM
Tari LeslieCHIEF SCIENTIFIC OFFICERSep 11 '23Sale0.9518,46917,509275,710Sep 13 04:24 PM
Tari LeslieCHIEF SCIENTIFIC OFFICERAug 14 '23Buy0.9710,0009,700294,179Aug 14 07:40 PM
Stein JeffreyPresident & CEOAug 08 '23Buy0.9650,00047,885331,602Aug 08 06:04 PM